Sun Pharma Starts Phytopharmaceutical Dengue Drug Trial for COVID-19, an Industrial Info Market Brief
Sun Pharma Starts Phytopharmaceutical Dengue Drug Trial for COVID-19, an Industrial Info Market Brief
Attachment: India Pharma
Indian pharma-giant Sun Pharmaceutical Industries Limited announced that it has commenced Phase II clinical trials on AQCH, a phytopharmaceutical experimental drug for treatment of COVID-19. The company has already received approval from the Drugs Controller General of India (DCGI) for conducting the trial.
The drug, which is being developed for treatment of dengue fever, has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy and hence is being tested as a potential treatment option for COVID-19.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021